Luke Ralston, a biomedical engineer and scientific reviewer at the FDA, has emphasised the need for transparency in AI regulation. The two main issues hampering the regulation are performance drift and data generalisation. Ralston stated that AI companies need to start monitoring and tracking the performance of their products once deployed and they also need to expand its representative data to cover more than just the demographics.
Cyber professionals are losing sleep over late night attacks
Hackers are biding their time and launching attacks when businesses can’t respond
